Related Experiment Video

Updated: Jul 14, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy

Julie R Brahmer1, David S Ettinger

  • 1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA. brahmju@jhmi.edu

Respirology (Carlton, Vic.)
|June 2, 2007
PubMed

Insights

Adjuvant chemotherapy improves survival for stage II and III non-small cell lung cancer. Neoadjuvant therapy shows promise for selected patients, though it is not yet standard care.

Area of Science:

  • Oncology
  • Thoracic Surgery

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer death.
  • Early-stage NSCLC has a poor survival rate, necessitating improved treatment strategies.
  • Adjuvant and neoadjuvant therapies have evolved significantly in the 21st century.

Purpose of the Study:

  • To review the evidence supporting adjuvant and neoadjuvant therapies for NSCLC.
  • To discuss the current standard of care for NSCLC treatment.
  • To highlight emerging research on predictive biomarkers for adjuvant therapy.

Main Methods:

  • Analysis of randomized trials published since 2004.
  • Review of data on adjuvant chemotherapy efficacy in different NSCLC stages.
  • Evaluation of neoadjuvant chemotherapy and chemoradiation outcomes.

Main Results:

  • Adjuvant chemotherapy demonstrates survival benefits for Stage II and III NSCLC.
  • Adjuvant chemotherapy's role in Stage I NSCLC remains controversial.
  • Neoadjuvant therapy shows potential but lacks established standard protocols.

Conclusions:

  • Adjuvant therapy is standard for Stage II and III NSCLC.
  • Neoadjuvant therapy is promising for select NSCLC patients.
  • Further research into predictive factors for adjuvant therapy is ongoing.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...